North American Regulatory and Commercial Engagement Advances U.S. Validation Pathway
Brisbane, Australia – February 5, 2026 – Ketim Technologies has completed a three-week North American engagement tour spanning San Francisco, Ottawa, Wallingford (Connecticut), Minneapolis, and San Jose, advancing regulatory planning, manufacturing alignment, and U.S. validation strategy.
The visit included participation in RESI JPM 2026 in San Francisco, followed by meetings with commercial and manufacturing partners to support Ketim’s in vitro diagnostic (IVD) development for postpartum depression risk prediction.
In Wallingford, Connecticut, the team toured Bio-Techne’s manufacturing facilities and progressed discussions regarding custom assay development to support U.S.-based validation studies. Additional meetings across Canada and the United States focused on regulatory strategy, clinical partnerships, and scaling production pathways.
Throughout the trip, Ketim engaged with investors and strategic partners, initiating discussions for its next funding round and strengthening relationships established through the Brisbane Economic Development Agency MedTech delegation.
Over the 21-day engagement, the team connected with more than 240 industry stakeholders and initiated follow-up conversations with multiple prospective investors for the company’s next capital raise.
The North American visit marks another step toward global deployment of Ketim’s predictive blood-based diagnostic for postpartum depression, reinforcing the company’s commitment to translating biomarker science into scalable clinical solutions.
For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au
